A qualitative study of perceptions of meaningful change in spinal muscular atrophy

BMC Neurology

Volumn 17, Issue 1, 2017, Pages

  McGraw, Sarah ^a   Qian, Ying ^b   Henne, Jeff ^a   Jarecki, Jill ^c   Hobby, Kenneth ^c   Yeh, Wei Shi ^d  

^a Henne Group   (United States)

^b SMA Foundation   (United States)

^c Cure SMA   (United States)

^d BIOGEN   (United States)

Author keywords

Meaningful change; Patient perspectives; Qualitative; Spinal muscular atrophy

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CAREGIVER; CHILD; CLINICAL ARTICLE; DAILY LIFE ACTIVITY; ENDURANCE; FATIGUE; FEMALE; FUNCTIONAL STATUS; GROUNDED THEORY; HAMMERSMITH FUNCTIONAL MOTOR SCALE; HUMAN; MALE; MOTOR DYSFUNCTION ASSESSMENT; MOTOR PERFORMANCE; OUTCOME ASSESSMENT; PHYSICIAN; QUALITATIVE RESEARCH; QUALITY OF LIFE; RESPIRATORY FUNCTION; SCHOOL CHILD; SPINAL MUSCULAR ATROPHY; SWALLOWING; UPPER LIMB MODULE; HEALTH CARE PERSONNEL; INFANT; MUSCULAR ATROPHY, SPINAL; PARENT; PATIENT-REPORTED OUTCOME; PRESCHOOL CHILD; PSYCHOLOGY; YOUNG ADULT;

ACTIVITIES OF DAILY LIVING; ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FEMALE; HEALTH PERSONNEL; HUMANS; INFANT; MALE; MUSCULAR ATROPHY, SPINAL; PARENTS; PATIENT REPORTED OUTCOME MEASURES; QUALITATIVE RESEARCH; QUALITY OF LIFE; YOUNG ADULT;

EID: 85016928031     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/s12883-017-0853-y     Document Type: Article

References (35)

1. Prior TW, Snyder PJ, Rink BD, Pearl DK, Pyatt RE, Mihal DC, et al. Newborn and carrier screening for spinal muscular atrophy. Am J Med Genet Part A. 2010;152:1608-16. doi: 10.1002/ajmg.a.33474.
2. Sugarman EA, Nagan N, Zhu H, Akmaev VR, Zhou Z, Rohlfs EM, et al. Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72>400 specimens. Eur J Hum Genet. 2012;20:27-32. doi: 10.1038/ejhg.2011.134.
3. Pearn J. Incidence, prevalence, and gene frequency studies of chronic childhood muscular atrophy. J Med Genet. 1978;15:409-13.
4. Ogino S, Wilson RB, Gold B. New insights on the evolution of the SMN1 and SMN2 region: simulation and meta-analysis for allele and haplotype frequency calculations. Eur J Hum Genet. 2004;12:1015-23. doi: 10.1038/sj.ejhg.5201288.
5. Arnold WD, Kassar D, Kissel JT. Spinal muscular atrophy: diagnosis and management in a new therapeutic era. Muscle Nerve. 2015;51:157-67. doi: 10.1002/mus.24497.
6. Kayadjanian N, Burghes A, Finkel RS, Mercuri E, Rouault F, Schwersenz I, et al. SMA-EUROPE workshop report: opportunities and challenges in developing clinical trials for spinal muscular atrophy in Europe. Orphanet J Rare Dis. 2013;8:44. doi: 10.1186/1750-1172-8-44.
7. Wang CH, Finkel RS, Bertini ES, Schroth M, Simonds A, Wong B, et al. Consensus statement for standard of care in spinal muscular atrophy. J Child Neurol. 2007;22:1027-49. doi: 10.1177/0883073807305788.
8. Kaufmann P, McDermott MP, Darras BT, Finkel R, Kang P, Oskoui M, et al. Observational study of spinal muscular atrophy type 2 and 3: functional outcomes over 1 year. Arch Neurol. 2011;68:779-86. doi: 10.1001/archneurol.2010.373.
9. Meldrum C, Scott C, Swoboda KJ. Spinal muscular atrophy genetic counseling access and genetic knowledge: parents' perspectives. J Child Neurol. 2007;22:1019-26. doi: 10.1177/0883073807305672.Spinal.
10. Markowitz J. A., Singh P, Darras BT. Spinal muscular atrophy: a clinical and research update. Pediatr Neurol. 2012;46:1-12. doi: 10.1016/j.pediatrneurol.2011.09.001.
11. Nurputra DK, Lai PS, Harahap NIF, Morikawa S, Yamamoto T, Nishimura N, et al. Spinal muscular atrophy: from gene discovery to clinical trials. Ann Hum Genet. 2013;77:435-63. doi: 10.1111/ahg.12031.
12. Zanetta C, Nizzardo M, Simone C, Monguzzi E, Bresolin N, Comi GP, et al. Molecular therapeutic strategies for spinal muscular atrophies: current and future clinical trials. Clin Ther. 2014;36:128-40. doi: 10.1016/j.clinthera.2013.11.006.
13. Waldman R, Bosboom W, van den Berg L, Wokke J, Iannaccone S, Vrancken A. Drug treatment for spinal muscular atrophy types II and III. Cochrane Database Syst Rev. 2011;(4):CD006282. doi: 10.1002/14651858.CD006282.pub4.
14. Kaufmann P, McDermott MP, Darras BT, Finkel RS, Sproule DM, Kang PB, et al. Prospective cohort study of spinal muscular atrophy types 2 and 3. Neurology. 2012;79:1889-97. doi: 10.1212/WNL.0b013e318271f7e4.
15. Kirschner J, Schorling D, Hauschke D, Rensing-Zimmermann C, Wein U, Grieben U, et al. Somatropin treatment of spinal muscular atrophy: a placebo-controlled, double-blind crossover pilot study. Neuromuscul Disord. 2014;24:134-42. doi: 10.1016/j.nmd.2013.10.011.
16. Chen T. Randomized, double-blind, placebo-controlled trial of Hydroxyurea in spinal muscular atrophy. Neurology. 2010;75:2190-7.
17. Mercuri E, Bertini E, Muntoni F. The Hammersmith motor functional scale for children with spinal muscular atrophy: a scale to test ability and monitor progress in children with limited ambulation. Eur J Paediatr Neurol. 2003;7:155-9.
18. O'Hagen J, Glanzman AM, M.P. M. An expanded version of the Hammersmith functional motor scale for SMA II and III patients. Neuromuscul Disord. 2007;17:693-7.
19. Glanzman AM, JM O'H, MP MD, Martens WB. Validation of the expanded Hammersmith functional motor scale in spinal muscular atrophy type II and III. J Child Neurol. 2011;26:1499-507.
20. Montes J, Glanzman AM, Mazzone ES, Martens WB, Dunaway S, Pasternak A, et al. SMA functional composite score: a functional measure in spinal muscular atrophy. Muscle and Nerve. 2015;52(6):942-7.
21. Sivo S, Mazzone E, Antonaci L, De Sanctis R, Fanelli L, Palermo C, et al. Upper limb module in non-ambulant patients with spinal muscular atrophy: 12 month changes. Neuromuscul Disord. 2015;25:212-5. doi: 10.1016/j.nmd.2014.11.008.
22. Seferian AM, Moraux A, Canal A, Decostre V, Diebate O, Le Moing AG, et al. Upper Limb Evaluation and One-Year Follow Up of Non-Ambulant Patients with Spinal Muscular Atrophy: An Observational Multicenter Trial. PLoS One 2015;10. doi: 10.1371/journal.pone.0121799.
23. Mazzone E, Bianco F, Martinelli D, Glanzman AM, Messina S, Sanctis R De, et al. Assessing upper limb function in nonambulant SMA patients: development of a new module. Neuromuscul Disord 2011;21:406-412. doi: 10.1016/j.nmd.2011.02.014.
24. Peay H, Hollin I, Fischer R, Bridges JFP. A community-engaged approach to quantifying caregiver preferences for the benefits and risks of emerging therapies for duchenne muscular distrophy. Clin Ther. 2014;36:624-37.
25. Crosby RD, Kolotkin RL, Williams GR. Defining clinically meaningful change in health-related quality of life. J Clin Epidemiol. 2003;56:395-407. doi: 10.1016/S0895-4356(03)00044-1.
26. FDA HHS. Guidance for industry use in medical product development to support labeling claims guidance for industry. Clin Fed Regist. 2009:1-39.
27. McLeod LD, Coon CD, Martin SA, Fehnel SE, Hays RD. Interpreting patient-reported outcome results: US FDA guidance and emerging methods. Expert Rev Pharmacoecon Outcomes Res. 2011;11:163-9.
28. Qian Y, McGraw S, Henne J, Jarecki J, Hobby K, Yeh W. Understanding the experiences and needs of individuals with Spinal Muscular Atrophy and their parents: a qualitative study n.d.
29. Main M. The Hammersmith functional motor scale for children with spinal muscular atrophy: a scale to test ability and monitor progress in children with limited ambulation. Eur J Paediatr Neurol. 2003;7:155-9.
30. Glaser B, Strauss A. The discovery of grounded theory: strategies for qualitative research. Chicago: Aldine Publishing Company; 1967.
31. Bradley EH, Curry LA, Devers KJ. Qualitative data analysis for health services research: developing taxonomy, themes, and theory. J Heal Serv Res. 2007;42:1758-72.
32. Dedoose: 6.1.11 n.d. dedoose.com. Accessed 2 Apr 2017.
33. Pera MC, Coratti G, Forcina N, Mazzone ES, Scoto M, Montes J, et al. Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy. BMC Neurol. 2017;17:39. doi: 10.1186/s12883-017-0790-9.
34. Rouault F, Christie-Brown V, Broekgaarden R, Gusset N, Henderson D, Marczuk P, et al. Disease impact on general well-being and therapeutic expectations of European type II and type III spinal muscular atrophy patients. Neuromuscul Disord. 2017; doi: 10.1016/j.nmd.2017.01.018.
35. Iannaccone ST, Hynan LS, Morton A, Buchanan R, Limbers CA, Varni JW. The PedsQL in pediatric patients with spinal muscular atrophy: feasibility, reliability, and validity of the pediatric quality of life inventory generic Core scales and neuromuscular module. Neuromuscul Disord. 2009;19:805-12. doi: 10.1016/j.nmd.2009.09.009.